Microbial Colonization Clinical Trial
Official title:
The Effects of Omega-3 Polyunsaturated Fatty Acids on the Infant Microbiome and Immunity
NCT number | NCT03297801 |
Other study ID # | H13-02523 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 22, 2014 |
Est. completion date | January 2017 |
Verified date | September 2017 |
Source | University of British Columbia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Prenatal supplementation with fish oil, rich in omega-3 polyunsaturated fatty acids, is widely recommended in Canada. The aim of this observational, prospective cohort study is to determine the effects of maternal fish oil supplements on the development of their infants' gut microbiota and immunity.
Status | Completed |
Enrollment | 109 |
Est. completion date | January 2017 |
Est. primary completion date | January 2017 |
Accepts healthy volunteers | |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - All mothers of infants in the Okanagan Valley are invited to participate in the study between the first day of delivery to until solid food is introduced into the infant's diet. - Healthy, full-term infants, who are predominantly breastfed by mothers who are or are not supplementing with fish oil. Mothers must also be healthy, i.e., asymptomatic and with no clinical indication of disease. - To remain within the inclusion criteria for this study, participants will be expected to be consistent (i.e. maintain the same type and amount of omega-3 PUFA intake or no intake) with whichever supplementation group they have decided to join for the entirety of the breast milk and infant stool donation period. In other words, the investigators will be asking the participants not to switch from one group to another which would happen by changing their omega-3 PUFA supplementation patterns. Exclusion Criteria: - Any infants who are ingesting juice or solid foods as part of their regular diet will be excluded from the study. - Any infants who are clinically ill (fever, contagious diseases, or active diarrhea) will be excluded from the study. - Any participants who decide to drastically change their omega-3 PUFA supplementation intake patterns (i.e. causing them to switch between study groups) will result in all subsequent samples to be excluded from the study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in infant fecal microbiota of the two groups. | Fecal microbiota will be measured by examining microbial taxa from infant stool every month from birth until 6-months of age or until solids are introduced. | 6 months | |
Secondary | Changes in infant short-chain fatty acid production of the two groups. | Changes in short-chain fatty acid production will be analyzed in infant stool through gas chromatography. | 6 months | |
Secondary | Changes in infant IgA in shed intestinal epithelial cells of the two groups. | We will examine the effects of fish oil on immunity by measuring fecal IgA concentrations using ELISA | 6 months | |
Secondary | Changes in infant cytokines in shed intestinal epithelial cells of the two groups. | We will examine the effects of fish oil on immunity by measuring fecal cytokines (TNF-a, IFN-y, IL-17) using real time PCR. | 6 months | |
Secondary | Compare occurrences of sickness and incidences of disease between the two groups. | Any incidences of disease in the infants will be closely monitored for the first 2 years of their lives. | 2 years | |
Secondary | Changes in breast milk IgA composition of the two groups. | Immune markers such as sIgA will be measured in breast milk using an addressable laser bead immunoassay (ALBIA) | 6 months | |
Secondary | Changes in breast milk cytokine composition of the two groups. | Immune markers such cytokines will be measured in breast milk using an addressable laser bead immunoassay (ALBIA) | 6 months | |
Secondary | Changes in breast milk lipid composition of the two groups. | Breast milk lipid concentrations will be analyzed using short-chain fatty acids | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05414994 -
Assessment of the Ocular Microbiome in Health and Disease
|
||
Completed |
NCT04769882 -
Er:YAG Laser Effects on Microbial Population in Conservative Dentistry
|
N/A | |
Completed |
NCT04766528 -
Effect of Diet on the Microbiota / Endoccanabinoidome Axis in Response to Physical Activity
|
N/A | |
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Completed |
NCT04122612 -
Shaping Microbiome in the First 1,000 Days of Life
|
||
Not yet recruiting |
NCT05405634 -
Microbiota in Chronic Anal Fissure and Its Association With Prognosis
|
||
Not yet recruiting |
NCT04895774 -
Ex Vivo Study of the Mechanism of Action of Active Ingredients on the Intestinal Microbiota
|
||
Recruiting |
NCT05992688 -
The Sweet Kids Study (Stevia on Weight and Energy Effect Over Time)
|
N/A | |
Recruiting |
NCT05502380 -
Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery
|
Phase 3 | |
Completed |
NCT05175833 -
Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19
|
Phase 2 | |
Recruiting |
NCT04836910 -
Microbiome and Polycystic Ovaries
|
||
Recruiting |
NCT05603650 -
Effects of Mouthrinses on the Microbiome of the Oral Cavity and GI Tract
|
N/A | |
Completed |
NCT04991818 -
MSC - OneBiome UX Pilot Study
|
N/A | |
Completed |
NCT05575050 -
Impact of Teeth Brushing in Ventilated COVID-19 Patients.
|
N/A | |
Completed |
NCT04374955 -
The Effect of Probiotic Added to Maternal Diet on Infantile Colic and Intestinal Microbiota Content
|
N/A | |
Recruiting |
NCT04140747 -
Transfer of Strictly Anaerobe Microbes From Mother to Child
|
||
Recruiting |
NCT04111471 -
The Use of A Prebiotic to Promote a Healthy Gut Microbiome in Pediatric Stem Cell Transplant Recipients
|
N/A | |
Suspended |
NCT03220282 -
The Milk, Growth and Microbiota Study
|
N/A | |
Completed |
NCT03422562 -
Probiotics and Intestinal Microbiome in Preterm Infants
|
Phase 3 | |
Recruiting |
NCT05695196 -
Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant
|
Phase 1 |